Prevention of community-acquired pneumonia with available pneumococcal vaccines

Nicola Principi, Susanna Esposito

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Community-acquired pneumonia (CAP) places a considerable burden on society. A substantial number of pediatric and adult CAP cases are due to Streptococcus pneumoniae, but fortunately there are effective vaccines available that have a significant impact on CAP-related medical, social, and economic problems. The main aim of this paper is to evaluate the published evidence concerning the impact of pneumococcal vaccines on the prevention of CAP in children and adults. Available data indicate that pneumococcal conjugate vaccines (PCVs) are effective in children, reducing all-cause CAP cases and bacteremic and nonbacteremic CAP cases. Moreover, at least for PCV7 and PCV13, vaccination of children is effective in reducing the incidence of CAP among adults. Recently use of PCV13 in adults alone or in combination with the pneumococcal polysaccharide vaccine has been suggested and further studies can better define its effectiveness in this group of subjects. The only relevant problem for PCV13 is the risk of a second replacement phenomenon, which might significantly reduce its real efficacy in clinical practice. Protein-based pneumococcal vaccines might be a possible solution to this problem.

Original languageEnglish
Article number30
JournalInternational Journal of Molecular Sciences
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

pneumonia
vaccines
Pneumococcal Vaccines
Vaccines
Pneumonia
Conjugate Vaccines
Pediatrics
Polysaccharides
Economics
Medical Economics
streptococcus
Social Problems
Streptococcus pneumoniae
polysaccharides
Proteins
Vaccination
economics
incidence
proteins
Incidence

Keywords

  • Community-acquired pneumonia
  • Pneumococcal conjugate vaccine
  • Pneumococcal polysaccharide vaccine
  • Pneumococcal prevention

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Computer Science Applications
  • Spectroscopy
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Prevention of community-acquired pneumonia with available pneumococcal vaccines. / Principi, Nicola; Esposito, Susanna.

In: International Journal of Molecular Sciences, Vol. 18, No. 1, 30, 01.01.2017.

Research output: Contribution to journalArticle

@article{856cd1a82d374198a05b0f3e737d8057,
title = "Prevention of community-acquired pneumonia with available pneumococcal vaccines",
abstract = "Community-acquired pneumonia (CAP) places a considerable burden on society. A substantial number of pediatric and adult CAP cases are due to Streptococcus pneumoniae, but fortunately there are effective vaccines available that have a significant impact on CAP-related medical, social, and economic problems. The main aim of this paper is to evaluate the published evidence concerning the impact of pneumococcal vaccines on the prevention of CAP in children and adults. Available data indicate that pneumococcal conjugate vaccines (PCVs) are effective in children, reducing all-cause CAP cases and bacteremic and nonbacteremic CAP cases. Moreover, at least for PCV7 and PCV13, vaccination of children is effective in reducing the incidence of CAP among adults. Recently use of PCV13 in adults alone or in combination with the pneumococcal polysaccharide vaccine has been suggested and further studies can better define its effectiveness in this group of subjects. The only relevant problem for PCV13 is the risk of a second replacement phenomenon, which might significantly reduce its real efficacy in clinical practice. Protein-based pneumococcal vaccines might be a possible solution to this problem.",
keywords = "Community-acquired pneumonia, Pneumococcal conjugate vaccine, Pneumococcal polysaccharide vaccine, Pneumococcal prevention",
author = "Nicola Principi and Susanna Esposito",
year = "2017",
month = "1",
day = "1",
doi = "10.3390/ijms18010030",
language = "English",
volume = "18",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "1",

}

TY - JOUR

T1 - Prevention of community-acquired pneumonia with available pneumococcal vaccines

AU - Principi, Nicola

AU - Esposito, Susanna

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Community-acquired pneumonia (CAP) places a considerable burden on society. A substantial number of pediatric and adult CAP cases are due to Streptococcus pneumoniae, but fortunately there are effective vaccines available that have a significant impact on CAP-related medical, social, and economic problems. The main aim of this paper is to evaluate the published evidence concerning the impact of pneumococcal vaccines on the prevention of CAP in children and adults. Available data indicate that pneumococcal conjugate vaccines (PCVs) are effective in children, reducing all-cause CAP cases and bacteremic and nonbacteremic CAP cases. Moreover, at least for PCV7 and PCV13, vaccination of children is effective in reducing the incidence of CAP among adults. Recently use of PCV13 in adults alone or in combination with the pneumococcal polysaccharide vaccine has been suggested and further studies can better define its effectiveness in this group of subjects. The only relevant problem for PCV13 is the risk of a second replacement phenomenon, which might significantly reduce its real efficacy in clinical practice. Protein-based pneumococcal vaccines might be a possible solution to this problem.

AB - Community-acquired pneumonia (CAP) places a considerable burden on society. A substantial number of pediatric and adult CAP cases are due to Streptococcus pneumoniae, but fortunately there are effective vaccines available that have a significant impact on CAP-related medical, social, and economic problems. The main aim of this paper is to evaluate the published evidence concerning the impact of pneumococcal vaccines on the prevention of CAP in children and adults. Available data indicate that pneumococcal conjugate vaccines (PCVs) are effective in children, reducing all-cause CAP cases and bacteremic and nonbacteremic CAP cases. Moreover, at least for PCV7 and PCV13, vaccination of children is effective in reducing the incidence of CAP among adults. Recently use of PCV13 in adults alone or in combination with the pneumococcal polysaccharide vaccine has been suggested and further studies can better define its effectiveness in this group of subjects. The only relevant problem for PCV13 is the risk of a second replacement phenomenon, which might significantly reduce its real efficacy in clinical practice. Protein-based pneumococcal vaccines might be a possible solution to this problem.

KW - Community-acquired pneumonia

KW - Pneumococcal conjugate vaccine

KW - Pneumococcal polysaccharide vaccine

KW - Pneumococcal prevention

UR - http://www.scopus.com/inward/record.url?scp=85007504825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007504825&partnerID=8YFLogxK

U2 - 10.3390/ijms18010030

DO - 10.3390/ijms18010030

M3 - Article

VL - 18

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 1

M1 - 30

ER -